Southern California Record

Monday, March 30, 2020

SCHIFF HARDIN: Aly Joins Center for Biosimilars Advisory Board

By Press release submission | Sep 11, 2019


Schiff Hardin issued the following announcement on Sept. 05.

Intellectual Property Practice Group Co-Leader Imron Aly has joined the advisory board for the Center for Biosimilars, an online resource for emerging pharmaceutical biotechnology that discusses the current landscape for advanced health care management with top industry thought leaders.

The board is composed of highly respected authorities in the biosimilars and healthcare industries, including health economics experts, pharmacists, managed care professionals, and key clinical specialists.

The Center for Biosimilars has featured Aly’s insights on important industry trends, such as “Pay-for-Delay,” drug prices, the Federal Drug Administration’s Purple Book, patent litigation, and inter partes review. 

Original source can be found here.

Want to get notified whenever we write about Schiff Hardin LLP ?

Sign-up Next time we write about Schiff Hardin LLP, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.

Organizations in this Story

Schiff Hardin LLP